GlassScriptPhysician profile
Tracy M Olson
NPI 1114638566
$2,390.58
in general payments reported to CMS, 2019-2025
12 companies · $37.86 in 2025
The $37.86 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $43.24 · 2023: $1,916 · 2024: $394 · 2025: $37.86.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,299 · Education: $48.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,298.50 |
| Education | $48.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $895.69 | 2023-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $478.42 | 2023-2024 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $246.87 | 2023-2024 | Uzedy, Austedo, Austedo Xr |
| Lundbeck LLC | $187.82 | 2023 | Rexulti |
| Axsome Therapeutics, INC. | $176.37 | 2023 | Auvelity, Sunosi |
| Alkermes, INC. | $113.72 | 2023 | Lybalvi, Vivitrol |
| Indivior INC. | $92.97 | 2023 | Perseris |
| Janssen Pharmaceuticals, INC | $63.09 | 2023 | Invega Sustenna, Invega, Invega Trinza |
| Otsuka America Pharmaceutical, INC. | $55.94 | 2023 | Abilify Maintena, Rexulti |
| Vanda Pharmaceuticals INC. | $43.24 | 2022 | |
| Bioxcel Therapeutics, INC. | $19.57 | 2023 | Igalmi |
| Itamar Medical INC | $16.88 | 2025 | Watchpatone |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tracy Olson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.